Single award · contract

LYCOV1404 Bebtelovimab

Award ID: W58P0522C0012

FY2022 · complete year · data as of 2026-07-11

A single federal award, with both ends of the trail linked.

$1.5B
Total award value

Award W58P0522C0012 is a contract from the Department of Defense to Eli Lilly and Company, $1.5B obligated, FY2022 to FY2023, for LYCOV1404 Bebtelovimab. The work is performed in Indiana. It is classified as NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals). Source

Agency ›
Department of Defense
Source
awarded→$1.5B
Recipient ›
Eli Lilly and Company
Source
performed in→
State ›
Indiana
Source

Award details

Award typeContract
PIIDW58P0522C0012
Action date2022
Period19 mo
Awarding agencyDepartment of Defense →
RecipientEli Lilly and Company →
Place of performanceIndiana →
CategoryNAICS 325412PSC 6505
Competed?Not recordedSource
Total (exact)$1,463,250,000

More awards to Eli Lilly and Company

Monoclonal Antibody LY-COV555
awarded 2020$1.4B
Purchase of a Total of 614,000 Doses of Combination Monoclonal Antibody
awarded 2021$1.3B
Purchase of 388,000 Doses of Monoclonal Antibody LY-COV016
awarded 2021$329.8M
Combination Monoclonal Antibody - Delivery Order for 100,000 Doses
awarded 2021$210M
All awards to this recipient →

More from Department of Defense

Contract HT940216C0001
awarded 2016$51.3B
SSN 802 and 803 Long Lead Time Material
awarded 2017$35.7B
LRIP Lot 12 Advance Acquisition Contract
awarded 2017$35.1B
Contract N0001902C3002
awarded 2001$34.2B
KC-X Modernization Program
awarded 2011$32B
All awards from this agency →
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.